Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Juvisy sur Orge, France Clinical Trials

A listing of Juvisy sur Orge, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (57) clinical trials

Cidofovir in Treating Patients With Stage IB Stage II Stage III or Stage IVA Cervical Cancer Who Are Receiving Chemotherapy and Radiation Therapy

OBJECTIVES: Primary - Determine the maximum tolerated dose of cidofovir when given as a radiosensitizer in patients with stage IB-IVA cervical cancer undergoing concurrent chemoradiotherapy. Secondary - Evaluate the influence of treatment on the expression of mRNA codons in HPV oncoproteins E6 and E7. - Determine the rate of local ...

Phase

6.27 miles

Learn More »

A Study of ABBV-181 in Participants With Advanced Solid Tumors

This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of ABBV-181. This study will also evaluate the safety and tolerability of ABBV-181 in combination with Rovalpituzumab Tesirine. The study will consist ...

Phase

6.87 miles

Learn More »

A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Lpilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

The purpose of this multicenter, Phase 1/2, open-label, study is to assess the safety and efficacy of rovalpituzumab tesirine administered in combination with nivolumab or nivolumab and ipilimumab in participants with extensive-stage small cell lung cancer (SCLC).

Phase

6.87 miles

Learn More »

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Study CC-90009-AML-001 is an open-label, Phase 1, dose escalation and expansion, first-in-human clinical study of CC-90009 in subjects with relapsed or refractory acute myeloid leukemia (AML). The dose escalation part (Part A) of the study will evaluate the safety and tolerability of escalating doses of CC-90009, The expansion part (Part ...

Phase

6.87 miles

Learn More »

A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

This is a Phase I, open-label, dose escalation and dose expansion study with a BID oral dose of tazemetostat. Subjects will be screened for eligibility within 14 days of the planned first dose of tazemetostat. A treatment cycle will be 28 days. Response assessment will be evaluated after 8 weeks ...

Phase

6.87 miles

Learn More »

A Study of the Safety Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

The primary purpose of this Phase 1, open-label study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-368 as a monotherapy and in combination with nivolumab in participants with locally advanced or metastatic solid tumors. The study will consist of 2 parts: ABBV-368 dose escalation and ABBV-368 tumor-specific ...

Phase

6.87 miles

Learn More »

Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer

The phase 1 study evaluats RAD001 in combination with radiotherapy in non-small cell lung cancer. First phase of the study:RAD001 (everolimus) will be administered per os every Monday, one week before then during the radiotherapy and will be continued for 3.5 weeks after the end of the radiotherapy. Chemotherapy is ...

Phase

6.87 miles

Learn More »

A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma

This is a multicenter, prospective phase Ib trial based on a dose escalation study design (3+3 traditional design) assessing four dose levels of Olaparib given with concomitant radiotherapy, followed by an expansion cohort.

Phase

6.87 miles

Learn More »

A Study of ABBV-428 an Immunotherapy in Subjects With Advanced Solid Tumors

This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of ABBV-428 when administered as monotherapy or in combination with nivolumab in participants with advanced solid tumors.

Phase

7.0 miles

Learn More »

Study of LXH254 and LTT462 in NSCLC

To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 and LTT462 combination and for the LXH254 and trametinib combination.

Phase

7.0 miles

Learn More »